Background:Ambroxol has been established for decades in the treatment of acute and chronic respiratory diseases. A reassessment of the benefit-risk was conducted recently. Objective: What new scientific data, relevant for the treatment of bronchopulmonary diseases, were published in the last decade? Method: Systematic literature search via http://www.pubmed.gov with the search term “ambroxol”, covering the publication period from 2006 to 2015. Nonrelevant publications were excluded manually. Results: 64 relevant publications could be identified covering both, clinical and preclinical research. Conclusion: The traditional indication of ambroxol as an expectorant is confirmed but new results revealed a better understanding of the various mechanisms of action of ambroxol and the benefits for special patient populations. The available data suggest the use of ambroxol as an adjuvant in anti-infective therapy, particularly in case of infections with biofilm-producing pathogens. Lungprotective properties are discussed in both infants and severely ill adult patients. First results in rare diseases, such as lysosomal storage disorders, show a potential benefit of ambroxol. However, final evidence for the clinical relevance in this special field has yet to be provided.
Manuel Plomer, Justus de Zeeuw
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2018 All rights reserved. iMedPub LTD Last revised : December 10, 2018